← Back to patent-cliff list
HA121-28
Tier C — Watch / tradeHA121-28
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EGFR, VEGFR, RET
Indications (approved)：Lung cancer, Non-small cell lung cancer, Medullary thyroid cancer, Oesophageal cancer, Bile duct cancer, Biliary tract cancer, Solid tumour
Regional status
US
-
EU
-
China
Phase II
2021-06-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HA121-28?
Approved indications include: Lung cancer, Non-small cell lung cancer, Medullary thyroid cancer, Oesophageal cancer, Bile duct cancer, Biliary tract cancer, Solid tumour.
When does the HA121-28 patent expire?
No public expiry year is available for HA121-28 yet; this page updates once verified.
How do I get a quote for HA121-28 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06